The management of febrile neutropenia in the posaconazole era: A new challenge?

Haematologica

Volumn 97, Issue 7, 2012, Pages 963-965

  Pagano, Livio ^a   Caira, Morena ^a   Cuenca Estrella, Manuel ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; CANDIDIASIS; EDITORIAL; FEBRILE NEUTROPENIA; HUMAN; INCIDENCE; MYCOSIS; MYELOID LEUKEMIA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; FEVER; FUNGI; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MANNANS; MYCOSES; NEUTROPENIA; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TRIAZOLES;

EID: 84863917144     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.062166     Document Type: Editorial

References (36)

1. Caira M, Mancinelli M, Leone G, Pagano L. Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. Med Mycol. 2011;49(Suppl 1):S13-6.
2. Pagano L, Caira M, Picardi M, Candoni A, Melillo L, Fianchi L, et al. Invasive aspergillosis in patients with acute leukemia: update on morbidity and mortality-SEIFEM-C Report. Clin Infect Dis. 2007;44(11): 1524-5.
3. Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66(Suppl 1):i5-14.
4. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545-52.
5. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845-51.
6. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138(9):705-13.
7. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004; 103(4):1527-33.
8. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-59.
9. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335-47.
10. Maertens JA, Nucci M, Donnelly JP. The role of antifungal treatment in hematology. Haematol. 2012;97(3):325-7.
11. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(3):327-60.
12. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update. Bone Marrow Transplant. 2011; 46(5):709-18.
13. Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz WJ, Karthaus M, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematol 2009;94(1):113-22.
14. Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, Spelman T, Cheng AC, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukaemia /myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012;97(3):459-63.
15. Busca A, Frairia C, Marmont F, Audisio E, Pecoraro C, de Rosa FG, et al. Posaconazole vs standard azoles for prevention of invasive fungal infections in patients with acute myeloid leukemia. Poster P088 at 5th TIMM (Trends in Medical Mycology) Congress, Valencia, Oct 2-5, 2011.
16. Candoni A, Simeone E, Caira M, Mazzuzzo M, Fanin R, Pagano L. Prophylaxis of invasive fungal diseases with posaconazole in acute myeloid leukemia. A real life experience. Abstract O804 at 16th EHA (European Hematology Association) Congress, June 11, 2011.
17. Egerer G, Geist MJ. Posaconazole prophylaxis in patients with acute myelogenous leukaemia--results from an observational study. Mycoses. 2011;54(Suppl 1):7-11.
18. Hahn J, Stifel F, Reichle A, Holler E, Andreesen R. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit. Mycoses. 2011;54(Suppl 1):12-6.
19. Lerolle N, Lafaurie M, Touratier S, Tournoud M, Raffoux E, Ribaud P, et al. Breakthrough invasive fungal infections in patients with hematological cancers receiving posaconazole prophylaxis: a four-year study. Abstract M-1521 ICAAC, Chicago Sept. 2011.
20. Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini FE, Thomas X, et al. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol. 2011;49(7):681-7.
21. Vehreschild JJ, Rüping MJ, Wisplinghoff H, Farowski F, Steinbach A, Sims R, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia: a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65(7):1466-71.
22. Khalafallah A, Maiwald M, Hannan T, Abell S, Staker J, Supperamohan A. Early implementation of antifungal therapy in the management of febrile neutropenia is associated with favourable outcome during induction chemotherapy for acute leukaemias. Intern Med J. 2011; doi:10.1111/j.1445-5994.2011.02638.x.
23. Lipp HP. Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses. 2011;54(Suppl 1):32-8.
24. Campoli P, Al Abdallah Q, Robitaille R, Solis NV, Fielhaber JA, Kristof AS, et al. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother. 2011;55(12):5732-9.
25. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41(9):1242-50.
26. Tan BH, Low JG, Chlebicka NL, Kurup A, Cheah FK, Lin RT, et al. Galactomannan-guided preemptive vs. empirical antifungals in the persistently febrile neutropenic patient: a prospective randomized study. Int J Infect Dis. 2011;15(5):e350-6.
27. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol. 2010;28(4):667-74.
28. Pagano L, Caira M, Nosari A, Cattaneo C, Fanci R, Bonini A, et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematol 2011;96(9):1366-70.
29. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48(8):1042-51.
30. Dignan FL, Evans SO, Ethell ME, Shaw BE, Davies FE, Dearden CE, et al. An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant 2009;44(1):51-6.
31. Oshima K, Kanda Y, Asano-Mori Y, Nishimoto N, Arai S, Nagai S, et al. Presumptive treatment strategy for aspergillosis in allogeneic haematopoietic stem cell transplant recipients. J Antimicrob Chemother. 2007;60(2):350-5.
32. Cuenca-Estrella M, Bassetti M, Lass-Flörl C, Rácil Z, Richardson M, et al. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011;66 (Suppl 1):i15-24.
33. Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother.2001;45(3):857-69.
34. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40(12):1762-9.
35. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant. 2011;doi: 10.1038/bmt.2011.178.
36. McCulloch E, Ramage G, Rajendran R, Lappin DF, Jones B, Warn P, et al. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis. J Clin Pathol. 2011;doi:10.1136/jcp.2011.090464